Skip to main content
. 2017 Feb 4;17:99. doi: 10.1186/s12885-017-3058-2

Fig. 1.

Fig. 1

Patient-derived GBM Stem Cells and Characterization of GBM Stem Cell Lines. a Glio 3, 4, 9, 11, 14 immunostaining. Cells are positive for stem cell markers CD133, A2B5, CD44, Nestin, SOX2, Bmi 1 and musashi. Cell nuclei were counterstained with DAPI. Scale bar: 100 μm. b GBM stem cell lines were treated with100μm temozolomide and viability determined after 72 h with MTS assay. Results displayed as percent viable cells compared to untreated controls. c U87 cells were treated with temozolomide at concentrations shown and viability determined at 72 h with MTS assay. *p < 0.001 compared to non-treated controls (NT)